Sign in
Explore the registryTrack Polatuzumab vedotin, zanubrutinib, rituximab, lenalidomide and prednisone as induction therapy's trials

Pola-ZR2P in Previously Untreated DLBCL

Polatuzumab Vedotin, Zanubrutinib, Rituximab, Lenalidomide and Prednisone as Induction TherapyOngoingRecruitingPhase 2Open NCT06664411 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…